original ) (raw )Neoadjuvant therapy prior to surgical resection for previously explored pancreatic cancer patients is associated with improved survival
Ammar Javed
HepatoBiliary Surgery and Nutrition
View PDFchevron_right
Does the Use of Neoadjuvant Therapy for Pancreatic Adenocarcinoma Increase Postoperative Morbidity and Mortality Rates?
Henry Pitt
Journal of Gastrointestinal Surgery, 2014
View PDFchevron_right
Neoadjuvant Chemotherapy Generates a Significant Tumor Response in Resectable Pancreatic Cancer Without Increasing Morbidity
Pierre-alain Clavien
Annals of Surgery, 2008
View PDFchevron_right
Long-term outcomes by response to neoadjuvant chemotherapy or chemoradiation in patients with resected pancreatic adenocarcinoma
Steve Abel
Journal of Gastrointestinal Oncology, 2019
View PDFchevron_right
Neoadjuvant Chemotherapy and Radiation for Patients with Locally Unresectable Pancreatic Adenocarcinoma: Feasibility, Efficacy, and Survival
Mary Digiorgi
Journal of Gastrointestinal Surgery, 2008
View PDFchevron_right
Impact of complications after resection of pancreatic cancer on disease recurrence and survival, and mediation effect of adjuvant chemotherapy: nationwide, observational cohort study
Ronald Van Dam
BJS open, 2023
View PDFchevron_right
Nationwide trends and outcomes associated with neoadjuvant therapy in pancreatic cancer: An analysis of 18 243 patients
Mohamed Adoma adam
Journal of surgical oncology, 2017
View PDFchevron_right
Neoadjuvant Treatment Strategies in Resectable Pancreatic Cancer
Aurélien Lambert
Cancers, 2021
View PDFchevron_right
Perioperative chemotherapy is associated with a survival advantage in early stage adenocarcinoma of the pancreatic head
Daniel Davenport
Surgery, 2016
View PDFchevron_right
Analyzing outcomes of neoadjuvant and adjuvant treatment for borderline-resectable pancreatic adenocarcinoma in the perioperative period at an academic institution
Emad Elquza
Annals of Pancreatic Cancer
View PDFchevron_right
Can Neoadjuvant Therapy in Pancreatic Cancer Increase the Pool of Patients Eligible for Pancreaticoduodenectomy?
Markus Buechler
Advances in surgery, 2017
View PDFchevron_right
Survival after surgical management of pancreatic adenocarcinoma: does curative and radical surgery truly exist?
K. Tran
Langenbeck's Archives of Surgery, 2005
View PDFchevron_right
Neoadjuvant treatment for locally advanced unresectable and borderline resectable pancreatic cancer: oncological outcomes at a single academic centre
Luis Sabater
ESMO Open, 2020
View PDFchevron_right
Are We Sure that Adjuvant Chemotherapy is the Best Approach for Resectable Pancreatic Cancer? Are We in the Era of Neoadjuvant Treatment? A Review of Current Literature
Ester Oneda , Alberto Zaniboni
View PDFchevron_right
Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer
David Nagorney
Annals of Surgery, 2019
View PDFchevron_right
Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma: NEOPA- a randomized multicenter phase III study (NCT01900327, DRKS00003893, ISRCTN82191749)
Karl Wegscheider
BMC cancer, 2014
View PDFchevron_right
Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) – study protocol for a national multicentre randomized controlled trial
Halfdan Sorbye
BMC Surgery
View PDFchevron_right
The Impact of Prolonged Chemotherapy to Surgery Interval and Neoadjuvant Radiotherapy on Pathological Complete Response and Overall Survival in Pancreatic Cancer Patients
Alan Livingstone
Clinical Medicine Insights: Oncology, 2020
View PDFchevron_right
Pathologic tumor response to neoadjuvant therapy in borderline resectable pancreatic cancer
Mauro Sollai
Hepatobiliary & Pancreatic Diseases International, 2019
View PDFchevron_right
Impact of adjuvant treatment modalities on survival outcomes in curatively resected pancreatic and periampullary adenocarcinoma
Nedim Turan , Veli Berk
Chinese journal of cancer research = Chung-kuo yen cheng yen chiu, 2015
View PDFchevron_right
Total neoadjuvant therapy for initially inoperable pancreatic cancer: A systematic review of phase 2-3 studies
Antonio Ghidini
View PDFchevron_right
Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma means no residual tumor: no need to assess “viability”
Henry Gomez
Annals of Diagnostic Pathology, 2012
View PDFchevron_right
Adenocarcinoma of the pancreas: the rationale for neoadjuvant therapy
Cosimo Sperti
Acta Bio Medica Atenei Parmensis, 2003
View PDFchevron_right
Neoadjuvant therapy in resectable pancreatic cancer: A critical review
Carmen Belli
Cancer Treatment Reviews, 2013
View PDFchevron_right
Could Total Neoadjuvant Therapy Followed by Surgical Resection Be the New Standard of Care in Pancreatic Cancer? A Systematic Review and Meta-Analysis
Alberto Fantin
Journal of Clinical Medicine, 2022
View PDFchevron_right